ESMO: Akeso, Summit's ivonescimab beats PD-1 in first chemo combo win in first-line NSCLC
18th October 2025 Uncategorised 0After upstaging Keytruda as monotherapy for the treatment of first-line non-small cell lung cancer in China, Akeso and Summit Therapeutics’ ivonescimab has shown it could delay tumor progression versus another PD-1 inhibitor as part of a combination with chemotherapy.
More: ESMO: Akeso, Summit's ivonescimab beats PD-1 in first chemo combo win in first-line NSCLC
Source: fierce